INDEX OF SUBJECTS FOR VOLUME 43

Abscesses
  bacteroides infections in children, 92
  "*S. milleri*" group, 405
Acinetobacter spp.
  A. baumannii, nosocomial transmission, 446
  infection in an ITU, 55
  multiresistant strains, 55
Acyclovir, usefulness as antiviral agent, 1
Adherence
  C. albicans to epithelial cells in AIDS/HIV infection, 452
  Candida spp. to fibronectin, 360
  of CNS isolated from endocarditis, 161
  M. pneumoniae to epithelial cells, 422
  properties of "*S. milleri*" group, 405
  staphylococci to epithelial cells, 161
  staphylococci to hydrogel-coated catheters, 133
  staphylococci to plastic surfaces, 161
Aggregation of platelets, by "*S. milleri*" group, 405
AIDS
  and adherence of *C. albicans*, 452
  and antiviral agents, 1
  co-infection with tuberculosis, 85
Amantadine, and influenza viruses, 1
Aminopeptidase activity, of *C. albicans*, 282
Anaerobes
  bacteroides infections in children, 92, 221
  gastrostomy site wound infections in children, 221
  taxonomy of gram-positive cocci, 148
Antibiotic resistance
  cephalosporin resistance of *S. typhimurium*, 294
  mechanisms of *P. aeruginosa*, 300
  multiple-drug-resistant strains of *M. tuberculosis*, 85
  penicillin, and *S. pneumoniae*, 237, 377
  review: 60 years of drug use and misuse, 395
Antibiotics and other antimicrobial substances
  antiviral agents, 1
  bactericidal activity of new 4-quinolones, 4
  ciprofloxacin microspheres, and *P. aeruginosa* biofilm, 368
  and co-infection of tuberculosis and HIV, 85
  potentiation against mycobacteria by ethambutol, 458
  review: 60 years of drug use and misuse, 395
  susceptibility of *S. pyogenes* to macrolides, 386
  susceptibility of *Y. enterocolitica* to β-lactams, 9
  sustained release, and biofilm infection, 368
  therapy for penicillin-resistant *S. pneumoniae*, 237
Antibodies
  against collagen binding protein of *S. aureus*, 328
  against epidermolytic toxin of *S. aureus*, 318
  against *M. leprae*, 115
  against OMP of *N. meningitidis*, 335
  against surface protein of *H. ducreyi*, 192
  see also Moncolonal antibodies
Antigens
  antigenic mimicry by *M. pneumoniae*, 422
  of *B. fragilis*, 99
  of *Brucella ovis*, 344
  of *M. leprae*, 115
  of *N. meningitidis*, 335
  of *P. aeruginosa*, 270
  of *Salmonella* serotype Typhi, 185
  of *V. cholerae*, 216
Antisera
  against *B. fragilis*, 99
  against surface protein of *H. ducreyi*, 192
Antiviral agents, for herpes, influenza and HIV, 1
Apoptosis, induction by LPS, 251
Automated laser fluorescence analysis (ALFA), 446
Azithromycin, susceptibility of *S. pyogenes*, 386

Bacteraemia
  β-haemolytic streptococci, 63
  bacteroides infections in children, 92
  coagulase-negative staphylococci, 161
  cyclophosphamide-induced, role of lymphocytes, 141
  virulence factors of *P. aeruginosa*, 258
Bacteroides spp.
  B. fragilis, antigens, 99
  gastrostomy site wound infections in children, 221
  immunological detection of *B. fragilis*, 99
  infections in children, 92, 221
BOOKS RECEIVED
  Bailliere's Clinical Infectious Diseases International Practice and Research Volume 1/Number 2 Strategies for Intracellular Survival of Microbes (Edited by D. G. Russell), 392
  Collins and Lyne's Microbiological Methods, 7th edition (C. H. Collins, P. M. Lyne and J. M. Grange), 310
  Current Clinical Topics in Infectious Diseases (Edited by J. S. Remington and M. N. Swartz), 78
  Hygiene for Spa Pools. Guidelines for their Safe Operation (Public Health Laboratory Service), 78
  Immunochemistry (Edited by C. J. van Oss and M. H. V. van Regenmortel) 310
  Meningococcal Disease (Edited by K. Cartwright), 311
  PCR-based Diagnostics in Infectious Disease (G. D. Erhlich and S. J. Greenberg), 310
  Retroviral Latency (M. A. Laughlin and R. J. Pomerantz), 235
Brucella ovis
  antigens, 344
  monoclonal antibodies, 344
Burkholderia cepacia
  characterisation by PCR ribotyping, 436
  and cystic fibrosis, 436

Campylobacter jejuni
  cytotoxin detection, 354
  isolated from the stomach, 75
Candida spp.
  binding to fibronectin, 360
  C. albicans, adherence to epithelial cells, 452
  C. albicans, in AIDS/HIV infection, 452
  C. albicans, identification by UAG test, 230
  C. albicans, metallopeptidase, 282
  C. tropicalis, identification by UAG test, 230
  identification by UAG test, 230
Capsule, novel capsular genotypes of *H. influenzae*, 120
Cattle, bovine model of listeria mastitis, 125
Cell culture
  adherence of *C. albicans* to epithelial cells, 452
  adherence of staphylococci to HEp-2 cells, 161
  detection of *C. jejuni* cytotoxin, 354
  ultrastructural studies of *Ehrlichia chaffeensis*, 411
Cephalosporins
  resistance of *S. typhimurium*, 294
  therapy of *S. pneumoniae* infections, 237
Cerebrospinal fluid
  detection of antibodies against *M. leprae*, 115
  effect of dexamethasone in meningitis model, 37
Cervical carcinoma, and HPV, 81, 430
Cetylpyridinium chloride, potentiation against mycobacteria by ethambutol, 458
Children
  bacteroides infections, 92, 221
  gastrostomy site wound infections, 221
Chlamydia trachomatis
  detection of mutations, 14
  major outer-membrane protein gene, 14
Chlorhexidine diacetate, potentiation against mycobacteria by ethambutol, 458
Cholera toxin, gene prevalence, 216
Chromatography, high performance liquid, 282
Ciprofloxacin
  and *P. aeruginosa* biofilm infection, 368
  sustained release microspheres, 368
Clarithromycin, susceptibility of *S. pyogenes*, 386

Clostridium perfringens
enterotoxin, 442
in sporadic diarrhoea, 442
Co-agglutination tests, for *Salmonella* serotype Typhi, 185
Cocci, taxonomy of gram-positive anaerobes, 148
Collagen binding protein of *S. aureus*, 328
Corticosterone, in LPS-induced apoptosis, 251
Cryptococcus neoformans, virulence in mice, 289
Culture media *see* Media
Cyclophosphamide-induced bacteraemia, 141
Cystic fibrosis, 270, 436
Cytotoxins
of *C. jejuni*, 354
of *E. coli*, 348

Dexamethasone, treatment of LPS-induced meningitis, 37
Diarrhoea, enterotoxigenic *C. perfringens*, 442
DNA
detection of mutations in *C. trachomatis*, 14
novel capsular genotypes of *H. influenzae*, 120
randomly amplified polymorphic (RAPD) analysis, 446

Ehrlichia chaffeensis, ultrastructural variation, 411
Electronmicroscopy
immuno-electronmicroscopy, 192
ultrastructure of *Ehrlichia chaffeensis*, 411
Electrophoresis
denaturing gradient gel analysis, 14
multilocus enzyme, 45, 377
pulsed-field gel, 50, 201, 208
see also SDS-PAGE
ELISA
antibodies to *S. aureus* collagen binding protein, 328
detection of anti-*M. leprae* antibodies in CSF, 115
raised IgM to *P. mirabilis* in rheumatoid arthritis, 177
surface protein of *H. ducreyi*, 192
Endocarditis
coagulase-negative staphylococci, 161
S. aureus infection, 328
"*S. milleri*" group, 405
Enterococcus spp.
E. faecalis, bactericidal activity of new 4-quinolones, 4
gastrostomy site wound infections, 221
Enterotoxins
of *C. perfringens*, 442
of *V. cholerae*, 216
Enzyme immunoassay (EIA), antibodies to *N. meningitidis*, 335
Epidemiology
Acinetobacter infection in an ITU, 55
bacteraemia due to β-haemolytic streptococci, 63
clonal analysis of *H. influenzae* type b, 45
co-infection with tuberculosis and HIV, 85
differentiation of *N. gonorrhoeae* serovars, 201, 208
heterogeneity of *M. kansasii* species, 156
human papillomavirus infection, 430
listeria mastitis, 125
nosocomial transmission of *A. baumannii*, 446
staphylococcal scalded skin syndrome, 318
V. cholerae, 216
Epididymitis, ovine, 344
Erythromycin, susceptibility of *S. pyogenes*, 386
Escherichia coli
bactericidal activity of new 4-quinolones, 4
enterohaemorrhagic (EHEC), 262
gastrostomy site wound infections in children, 221
in haemolytic uraemic syndrome, 348
in haemorrhagic colitis, 348
identification by the RAPIDEC ur system, 72
monoclonal antibody, 262
mouse model of chronic pyelonephritis, 33
in urinary tract infections, 72
verotoxin producing (VTEC), 262, 348
Ethambutol, potentiation of anti-mycobacterial drugs, 458
Exfoliative (epidermolytic) toxin, 318
Exo-enzyme S, in *P. aeruginosa* bacteraemia, 258
Exotoxin A, of *P. aeruginosa*, 169

Faeces, characterisation of verotoxin-producing *E. coli*, 348
Famciclovir, 1
Fibrinogen binding, by "*S. milleri*" group, 405
Fibronectin binding
by *Candida* spp., 360
by "*S. milleri*" group, 405
by staphylococci, 161
Flagellins, of *P. aeruginosa*, 270
Flow cytometry, 277

Ganciclovir, 1
Gastric ulcer, and *C. jejuni*, 75
Gastro-enteritis, rotavirus infection, 397
Gastrostomy site wound infections in children, 221
Genital warts, 81, 430

Haemolytic uraemic syndrome, 348
Haemophilus
H. ducreyi, antibodies against, 192
H. ducreyi, properties of 24-kDa surface protein, 192
H. influenzae, clonal analysis, 45
H. influenzae, novel capsular genotypes, 120
H. influenzae type b, 45, 120
Haemorrrhagic colitis, 348
Heart transplant patient, 189
Hepatitis B, chronic, 277
Hepatitis B virus, T cell response, 277
Herpes virus, and antiviral agents, 1
Histoplasma capsulatum, killing by macrophages, 224
HIV infection
and adherence of *C. albicans*, 452
and antiviral agents, 1
co-infection with *M. tuberculosis*, 85
Human papillomaviruses
carcinogenesis, 81
detection in cervical carcinoma tissues, 430
epidemiology, 430
pathogenesis, 81
serology, 81
vaccine development, 81
Hybridisation of DNA
novel capsular genotypes of *H. influenzae*, 120
Hydrogel coating, and adhesion of staphylococci, 133
Hydrophobicity, of staphylococci, 133, 161

Immune response
in co-infection with tuberculosis and HIV, 85
in cyclophosphamide-induced bacteraemia, 141
to OMP of *N. meningitidis*, 335
to *P. aeruginosa* in cystic fibrosis, 270
to rotavirus, 397
to *S. aureus* collagen binding protein, 328
to surface protein of *H. ducreyi*, 192
Immuno-electronmicroscopy, surface protein of *H. ducreyi*, 192
Immunoblotting
antibodies to *N. meningitidis*, 335
surface protein of *H. ducreyi*, 192
Immunofluorescence microscopy, detection of *B. fragilis*, 99
Immunoglobulins
IgA, in cyclosphosphamide-induced bacteraemia, 141
IgG response to *P. aeruginosa*, 270
IgG response to *S. aureus* collagen binding protein, 328
raised IgM to *P. mirabilis* in rheumatoid arthiritis, 177
Influenza viruses, and antiviral agents, 1
Intensive therapy unit, *Acinetobacter* infection in, 55
Iron
supply of micrococci by α-ketoacids, 26
supply of staphylococci by α-ketoacids, 26

α-Ketoacids, supply of iron to staphylococci and micrococci, 26

β-Lactamases
and gastrostomy site wound infections, 221
of *P. aeruginosa*, 300

of *S. typhimurium*, 294
of *Yersinia enterocolitica*, 9
Latex agglutination tests, for *Salmonella* serotype Typhi, 185
Legionella pneumophila
monoclonal antibody subgroups, 50
subtyping serogroup 1 strains, 50
Legionnaires' disease, 50
Leprosy, 115
Leptospira spp., early diagnosis of infection, 110
Leptospirosis, early diagnosis by PCR, 110
Limiting dilution analysis, 277
Lipopolysaccharide (LPS)
of *Brucella ovis*, 344
and dexamethasone in meningitis model, 37
induction of apoptosis in lymphocytes, 251
Listeria monocytogenes
bovine model of listeria mastitis, 125
Lymphocytes
induction of apoptosis by LPS, 251
role in chronic hepatitis B, 277
role in cyclosphosphamide-induced bacteraemia, 141

Macrophage colony stimulating factor, 224
Macrophages
interactions with mycoplasmas, 239
killing of *H. capsulatum*, 224
monocyte-derived, 224
Mastitis, listeria, bovine model, 125
Media
Rambach agar for identification of salmonellae, 68
SM-ID, for identification of salmonellae, 68
Meningitis
clonal analysis of *H. influenzae* type b, 45
dexamethasone treatment in rabbit model, 37
penicillin-resistant *S. pneumoniae*, 237
Meningococci *see Neisseria meningitidis*
Metallopeptidase, of *C. albicans*, 282
Micrococci, iron supply by α-ketoacids, 26
Monoclonal antibodies
against *B. fragilis*, 99
against *Brucella ovis*, 344
against *E. coli* O157:H7, 262
against *L. pneumophila*, 50
against *M. leprae*, 115
against *M. pneumoniae*, 422
against *P. aeruginosa*, 169
Monocyte-derived macrophages, fungicidal activity, 224
Mouse model
E. coli in chronic pyelonephritis, 33
induction of apoptosis in lymphocytes by LPS, 251
P. aeruginosa bacteraemia, 258
protection against *B. ovis*, 344
role of exotoxin A in *P. aeruginosa* infection, 169
role of lymphocytes in cyclophosphamide-induced bacteraemia, 141
staphylococcal scalded skin syndrome, 318
virulence of *C. neoformans*, 289
Mycobacteria
amplification of 16S–23S spacer region, 156
heterogeneity of *M. kansasii* species, 156
M. haemophilum, 16S rRNA sequence analysis, 189
M. haemophilum, from heart transplant patient, 189
M. leprae, antigens, 115
M. leprae, detection of antibodies in CSF, 115
M. leprae, monoclonal antibodies, 115
M. tuberculosis, co-infection with HIV, 85
M. tuberculosis, epidemiology, 85
M. tuberculosis, multiple-drug-resistant strains, 85
potentiation of antibacterial compounds by ethambutol, 458
Mycoplasmas
M. pneumoniae, molecular mimicry, 422
M. pneumoniae, monoclonal antibodies, 422
phagocytosis of, 239

Neisseria
N. gonorrhoeae, differentiation of serovars, 201, 208
N. gonorrhoeae, requiring arginine, hypoxanthine or uracil, 208
N. meningitidis, antibody response, 335
N. meningitidis, outer-membrane protein, 335
Neuraminidase, of influenza virus, 1
Nosocomial infections
Acinetobacter infection in an ITU, 55
transmission of *A. baumannii*, 446

Otitis media, 237

Penciclovir, 1
Penicillin resistance
of *P. aeruginosa*, 300
of *S. pneumoniae*, 237, 377
Peptococcus spp., taxonomy, 148
Peptostreptococcus spp.
gastrostomy site wound infections, 221
taxonomy, 148
Peritonitis, bacteroides infections in children, 92
Phagocytosis
of mycoplasmas, 239
P. aeruginosa by PMNLs, 169
Plasmids, and antibiotic resistance of *S. typhimurium*, 294
Plastic surfaces, adherence of staphylococci, 133, 161
Pneumonia, *S. pneumoniae* infection, 237
Polymerase chain reaction
amplification of mycobacterial 16S–23S spacer region, 156
characterisation of *Burkholderia cepacia*, 436
detection of human papillomavirus, 430
differentiation of serovars of *N. gonorrhoeae*, 201
early diagnosis of leptospirosis, 110
genotyping of VTEC, 348
heterogeneity of *M. kansasii* species, 156
novel capsular genotypes of *H. influenzae*, 120
screening for *A. baumannii* transmission, 446
Polymorphonuclear leucocytes (PMNL)
effects of *P. aeruginosa* exotoxin A, 169
interactions with mycoplasmas, 239
phagocytosis of *P. aeruginosa*, 169
Polystyrene, adhesion of staphylococci, 133, 161
Polyurethane, adhesion of staphylococci, 133
Proteases, in *P. aeruginosa* bacteraemia, 258
Proteins
Barber protein of *Salmonella* serotype Typhi, 185
collagen binding, of *S. aureus*, 328
outer-membrane, of *Brucella ovis*, 344
outer-membrane, of *C. trachomatis*, 14
outer-membrane, of *N. meningitidis*, 335
outer-membrane, typing of *H. influenzae* type b, 45
protein IB of *N. gonorrhoeae*, 201
surface, of *H. ducreyi*, 192
Proteus mirabilis
raised levels of IgM in rheumatoid arthritis, 177
Pseudomonas aeruginosa
bacteraemia, 141, 258
in cyclophosphamide-induced bacteraemia, 141
in cystic fibrosis, 270
device-associated biofilm infection, 368
exo-enzyme S, 258
exotoxin A, 169
flagellins, 270
IgG response to infection, 270
mechanisms of antibiotic resistance, 300
monoclonal antibody, 169
proteases, 258
and sustained release ciprofloxacin microspheres, 368
Pyelonephritis, chronic, animal model, 33
Pyrolysis mass spectrometry
taxonomy of gram-positive anaerobic cocci, 148

4-Quinolones, bactericidal activity of new agents, 4

Rabbit model
ciprofloxacin microspheres in biofilm infection, 368
dexamethasone treatment of LPS-induced meningitis, 37

Radiolabelling, 133
RAPIDEC ur system, 72
Restriction enzyme analysis
  16S rRNA of *M. haemophilum*, 189
  prevalence of *V. cholerae* genes, 216
  subtyping *L. pneumophila* strains, 50
  typing of *N. gonorrhoeae*, 208
Restriction fragment length polymorphism analysis
  of *V. cholerae*, 216
  VTEC genotyping, 348
Rheumatoid arthritis, 176
Ribotyping
  of *Burkholderia cepacia*, 436
  serovars of *N. gonorrhoeae*, 208
Ritter's disease, 318
Rotavirus infection, human immunity, 397
Roxithromycin, susceptibility of *S. pyogenes*, 386

Salmonellae
  detection of Barber protein and Vi antigen, 185
  new selective media for identification, 68
  rapid diagnosis of typhoid fever, 185
  S. typhimurium, β-lactamase production, 294
  S. typhimurium, cephalosporin resistance, 294
  S. typhimurium, plasmid, 294
  serotype Typhi, 185
SDS-PAGE, characterisation of surface protein of *H. ducreyi*, 192
Septicaemia, *S. aureus* infection, 328
Serology
  cytotoxicity seroneutralisation assay for *E. coli*, 348
  human papillomaviruses, 81
  raised IgM to *P. mirabilis* in rheumatoid arthritis, 177
  rapid diagnosis of typhoid fever, 185
Shrimp production, and *V. cholerae* isolates, 216
Sialidase, of influenza virus, 1
Siderophores, 26
Silicone, adherence of staphylococci, 161
Slime production, staphylococcal, 161
Southern blotting, detection of human papillomavirus, 430
Staphylococcal scalded skin syndrome, 318
Staphylococci
  adherence to plastic surfaces, 133, 161
  coagulase-negative, 36, 161
  hydrophobicity, 133, 161
  iron supply by α-ketoacids, 26
  pathogenicity, and infective endocarditis, 161
  S. aureus, bactericidal activity of new 4-quinolones, 4
  S. aureus, adhesion to plastic surfaces, 133
  S. aureus, collagen binding protein, 328
  S. aureus, in endocarditis, 328
  S. aureus, exfoliative toxin, 318
  S. aureus, septicaemia, 328
  S. aureus, staphylococcal scalded skin syndrome, 318
  S. epidermidis, bactericidal activity of new 4-quinolones, 4
  S. epidermidis, adhesion to plastic surfaces, 133
Stomach, *C. jejuni* in, 75
Streptococci
  β-haemolytic, 63
  bacteraemia, 63
  "*S. milleri*" group, in abscesses, 405
  "*S. milleri*" group, in endocarditis, 405
  "*S. milleri*" group, potential pathogenic properties, 405
  S. pneumoniae, bactericidal activity of new 4-quinolones, 4
  S. pneumoniae, penicillin-resistant, 237, 377
  S. pneumoniae, therapy for infections, 237
  S. pyogenes, susceptibility to macrolides, 386
Superoxide anions, 224

T cells, role in pathogenesis of chronic hepatitis B, 277
Taxonomy
  of gram-positive anaerobic cocci, 148
  proposed changes of bacterial names, 315
  proposed new bacterial taxa, 315
Toxic epidermal necrolysis, 318
Toxins
  cholera toxin, 216
  exfoliative (epidermolytic), 318
  exotoxin A of *P. aeruginosa*, 169
  see also Cytotoxins; Enterotoxins
Tuberculosis, co-infection with AIDS, 85
Tumour necrosis factor
  effect of dexamethasone in meningitis model, 37
  and LPS-induced apoptosis, 251
Typhoid fever, rapid diagnosis, 185

Umbelliferyl-labelled galactosaminide, 230
Urinary pathogens, identification by the RAPIDEC ur system, 72

Vaccines
  against *Brucella ovis*, 344
  against human papillomaviruses, 81
Valaciclovir, 1
Vibrio cholerae
  cholera toxin, 216
  heat-stable enterotoxin, 216
  isolates from shrimp farms, 216
  O antigen expression, 216
Virulence factors
  Cryptococcus neoformans, 289
  P. aeruginosa, 169, 258
  "*S. milleri*" group, 405

Wound infections
  bacteroides infections in children, 92
  gastrostomy site in children, 221

Yersinia enterocolitica
  β-lactamases, 9
  susceptibility to β-lactam agents, 9

Zidovudine, and HIV infection, 1

INDEX OF AUTHORS FOR VOLUME 43

ABED Y, BOLLET C, DE MICCO P. Demonstration of *Mycobacterium kansasii* species heterogeneity by amplification of the 16S–23S spacer region, 156
AHUJA VARINDER, *see* GUPTA *et al.*, 33
AIRAKSINEN U, *see* IDÄNPÄÄN-HEIKKILÄ *et al.*, 335
AKUESHI C O, *see* IROKANULO AND AKUESHI, 289
AMARAPURKAR D N, *see* CHAVAN *et al.*, 277
AOKI AKEMI, *see* NORIMATSU *et al.*, 251

BARLOW DIANA, *see* ZAPPE *et al.*, 189
BARRAULT CHRISTINE, *see* EL MOUDNI *et al.*, 282
BARTL A, *see* JACOBS *et al.*, 422
BATCHELOR B I F. Identification of urinary pathogens by the RAPIDEC® ur system, 72
BEER W, *see* HEUCK *et al.*, 26
BELL S M, *see* PHAM *et al.*, 9
BILBE G, *see* ROONEY *et al.*, 37
BIRARELLI P, *see* SANTONI *et al.*, 360
BIRKENHEAD C, *see* SAHAY *et al.*, 75
BIRLEY H D L, HART C A, STACEY S N. Human papillomaviruses and the genital tract: old virus, new developments, 81
BIRTLES R J, *see* LÜCK *et al.*, 50
BOLLET C, *see* ABED *et al.*, 156
BOLTON INGRID J, *see* ZAPPE *et al.*, 189
BOURRY A, POUTREL B, ROCOURT J. Bovine mastitis caused by *Listeria monocytogenes*: characteristics of natural and experimental infections, 125
BOWDEN R A, CLOECKAERT A, ZYGMUNT M S, DUBRAY G. Outer-membrane protein- and rough lipopolysaccharide-specific monoclonal antibodies protect mice against *Brucella ovis*, 344
BRETT M M, *see* MPAMUGO *et al.*, 442
BROADLEY S J, JENKINS P A, FURR J A, RUSSELL A D. Potentiation of the effects of chlorhexidine diacetate and cetylpyridinium chloride on mycobacteria by ethambutol, 458
BROOK I. Bacteroides infections in children, 92
BROOK I. Microbiology of gastrostomy site wound infections in children, 221
BROWN P D, GRAVEKAMP C, CARRINGTON D G, VAN DE KEMP H, HARTSKEERL R A, EDWARDS C N, EVERARD C O R, TERPSTRA W J, LEVETT P N. Evaluation of the polymerase chain reaction for early diagnosis of leptospirosis, 110
BROWN R, *see* PATRICK *et al.*, 99
BRUMMER E, *see* DESAI *et al.*, 224

CAPRIOLI A, LUZZI IDA, GIANVITI ALESSANDRA, RUSSMANN H, KARCH H. Pheno-genotyping of verotoxin 2 (VT2)-producing *Escherichia coli* causing haemorrhagic colitis and haemolytic uraemic syndrome by direct analysis of patients' stools, 348
CARNIEL E, *see* PHAM *et al.*, 9
CARRINGTON D G, *see* BROWN *et al.*, 110
CHALLACOMBE S J, *see* SWEET *et al.*, 452
CHANG D Y, HSIEH C Y, CHEN R J, LEE S C, HUANG S-C. Comparison of detection of human papillomavirus 16 DNA in cervical carcinoma tissues by Southern blot hybridisation and nested polymerase chain reaction, 430
CHATTOPADHYAY P, *see* IDÄNPÄÄN-HEIKKILÄ *et al.*, 335
CHAVAN SANGEETA S, AMARAPURKAR D N, KALRO R H, CHIPLUNKAR SHUBHADA V. Frequency analysis of proliferating and cytotoxic T cells in livers and peripheral blood of patients with chronic hepatitis B, 277
CHEN H Y, YUAN MEI, LIVERMORE D M. Mechanisms of resistance to β-lactam antibiotics amongst *Pseudomonas aeruginosa* isolates collected in the UK in 1993, 300
CHEN R J, *see* CHANG *et al.*, 430
CHEN SHENG-MIN, *see* POPOV *et al.*, 411
CHIPLUNKAR SHUBHADA V, *see* CHAVAN *et al.*, 277
CHOW V T K, *see* POH *et al.*, 201
CHRISTENSSON B, *see* RYDING *et al.*, 328
CLARK C G, JOHNSON S, JOHNSON R P. Further characterisation of a monoclonal antibody reactive with *Escherichia coli* O157:H7, 262
CLOECKAERT A, *see* BOWDEN *et al.*, 344
COOKSON SHARON, *see* SWEET *et al.*, 452
CREE ROSEMARY G A, PHILLIPS I, NOBLE W C. Adherence characteristics of coagulase-negative staphylococci isolated from patients with infective endocarditis, 161
CROOK D W M, *see* LEAVES *et al.*, 120
CROWE M, TOWNER K J, HUMPHREYS H. Clinical and epidemiological features of an outbreak of acinetobacter infection in an intensive therapy unit, 55

DALSGAARD A, SERICHANTALERGS O, SHIMADA T, SETHABUTR O, ECHEVERRIA P. Prevalence of *Vibrio cholerae* with heat-stable enterotoxin (NAG-ST) and cholera toxin genes; restriction fragment length polymorphisms of NAG-ST genes among *V. cholerae* O serogroups from a major shrimp production area in Thailand, 216
DAMANI N, *see* PATRICK *et al.*, 99
DASCHNER F D, *see* GRUNDMANN *et al.*, 446
DEB MANORAMA, *see* PANDYA *et al.*, 185
DE MICCO P, *see* ABED *et al.*, 156
DENAMUR E, *see* SAYADA *et al.*, 14
DERRICK M R, *see* JOHN *et al.*, 133
DESAI GOPI, NASSAR F, BRUMMER E, STEVENS D A. Killing of *Histoplasma capsulatum* by macrophage colony stimulating factor-treated human monocyte-derived macrophages: role for reactive oxygen intermediates, 224
DILLON JO-ANNE R, *see* LI AND DILLON, 208
DJEU J Y, *see* SANTONI *et al.*, 360
DODANLI S, *see* VAHABOGLU *et al.*, 294
DONOVAN T, *see* MPAMUGO *et al.*, 442
DROBNIEWSKI F A, POZNIAK A L. UTTLEY A H C. Tuberculosis and AIDS, 85
DUBRAY G, *see* BOWDEN *et al.*, 344

ECHEVERRIA P, *see* DALSGAARD *et al.*, 216
EDWARDS C N, *see* BROWN *et al.*, 110
ELION J, *see* SAYADA *et al.*, 14
EL MOUDNI B, RODIER MARIE-HÉLÈNE, BARRAULT CHRISTINE, GHAZALI M, JACQUEMIN J L. Purification and characterisation of a metallopeptidase of *Candida albicans*, 282
EVERARD C O R, *see* BROWN *et al.*, 110

FALLA T J, *see* LEAVES *et al.*, 120
FENG HUI-MIN, *see* POPOV *et al.*, 411
FREDERIKSEN W, URSING J. Proposed new bacterial taxa and proposed changes of bacterial names published during 1994 and considered to be of interest to medical or veterinary bacteriology, 315
FRIEDLAND I R, *see* STRACHAN AND FRIEDLAND, 237
FRISK A, ROGGEN E L, LAGERGÅRD TERESA. Localisation and immunological properties of a 24-kDa surface protein of *Haemophilus ducreyi*, 192
FURR J R, *see* BROADLEY *et al.*, 458
FURUYA N, *see* HIRAKATA *et al.*, 258
FURUYA NOBUHIKO, *see* HIRAKATA *et al.*, 141

GAMERO A, *see* SANTONI *et al.*, 360
GANGULY N K, *see* GUPTA *et al.*, 33
GEMMELL C G. Staphylococcal scalded skin syndrome, 318
GESLIN P, *see* REICHMANN *et al.*, 377
GHAZALI M, *see* EL MOUDNI *et al.*, 282
GIAMMANCO GIOVANNI, *see* PIGNATO *et al.*, 68
GIAMMANCO GIUSEPPE, *see* PIGNATO *et al.*, 68
GIANVITI ALESSANDRA, *see* CAPRIOLI *et al.*, 348
GRANDCHAMP B, *see* SAYADA *et al.*, 14
GRAVEKAMP C, *see* BROWN *et al.*, 110
GREENWOOD D. Tarnished gold: sixty years of antimicrobial drug use and misuse, 395

GRUNDMANN H, SCHNEIDER CH, TICHY H V, SIMON R, KLARE I, HARTUNG DORIS, DASCHNER F D. Automated laser fluorescence analysis of randomly amplified polymorphic DNA: a rapid method for investigating nosocomial transmission of *Acinetobacter baumannii*, 446
GUIYOLE A, *see* PHAM *et al.*, 9
GÜNTHER ELISABETH, *see* REICHMANN *et al.*, 377
GUPTA R, GANGULY N K, AHUJA VARINDER, JOSHI KUSEM, SHARMA SAROJ. An ascending non-obstructive model for chronic pyelonephritis in BALB/c mice, 33

HAKENBECK REGINE, *see* REICHMANN *et al.*, 377
HALL L M C, *see* VAHABOGLU *et al.*, 294
HANDLEY PAULINE S, *see* JOHN *et al.*, 133
HARDY M J, *see* PHAM *et al.*, 9
HART C A, *see* BIRLEY *et al.*, 81
HARTSKEERL R A, *see* BROWN *et al.*, 110
HARTUNG DORIS, *see* GRUNDMANN *et al.*, 446
HAWKEY P M, *see* SAHAY *et al.*, 75
HELBIG J H, *see* LÜCK *et al.*, 50
HEUCK DAGMAR, BEER W, REISSBRODT R. Iron supply of staphylococci and of micrococci by α-ketoacids, 26
HILLIER VALERIE F, *see* JOHN *et al.*, 133
HIRAKATA Y, FURUYA N, TATEDA K, MATSUMOTO T, YAMAGUCHI K. The influence of exo-enzyme S and proteases on endogenous *Pseudomonas aeruginosa* bacteraemia in mice, 258
HIRAKATA YOICHI, FURUYA NOBUHIKO, TATEDA KAZUHIRO, YAMAGUCHI KEIZO. A protective role for lymphocytes in cyclophosphamide-induced endogenous bacteraemia in mice, 141
HØIBY E A, *see* IDÄNPÄÄN-HEIKKILÄ *et al.*, 335
HSIEH C Y, *see* CHANG *et al.*, 430
HUANG S-C, *see* CHANG *et al.*, 430
HUMPHREYS H, *see* CROWE *et al.*, 55

IDÄNPÄÄN-HEIKKILÄ I, HØIBY E A, CHATTOPADHYAY P, AIRAKSINEN U, MICHAELSEN T M, WEDEGE E. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease, 335
IROKANULO E A O, AKUESHI C O. Virulence of *Cryptococcus neoformans* serotypes A, B, C and D for four mouse strains, 289
ITOH K, *see* MISAWA *et al.*, 354

JACOBS E, BARTL A, OBERLE K, SCHILTZ E. Molecular mimicry by *Mycoplasma pneumoniae* to evade the induction of adherence inhibiting antibodies, 422
JACQUEMIN J L, *see* EL MOUDNI *et al.*, 282
JENKINS P A, *see* BROADLEY *et al.*, 458
JIN HONG L, *see* SANTONI *et al.*, 360
JOHN STEPHANIE F, HILLIER VALERIE F, HANDLEY PAULINE S, DERRICK M R. Adhesion of staphylococci to polyurethane and hydrogel-coated polyurethane catheters assayed by an improved radiolabelling technique, 133
JOHNSON R P, *see* CLARK *et al.*, 262
JOHNSON S, *see* CLARK *et al.*, 262
JOSHI KUSEM, *see* GUPTA *et al.*, 33

KALRO R H, *see* CHAVAN *et al.*, 277
KARCH H, *see* CAPRIOLI *et al.*, 348
KATOCH KIRAN, *see* PATIL *et al.*, 115
KERMANI P, *see* LAGACÉ *et al.*, 270
KERR M A, *see* SENIOR *et al.*, 176
KLARE I, *see* GRUNDMANN *et al.*, 446
KRISTENSEN B, SCHØNHEYDER H C. A 13-year survey of bacteraemia due to β-haemolytic streptococci in a Danish county, 63

LAGACÉ J, PÉLOQUIN L, KERMANI P, MONTIE T C. IgG subclass responses to *Pseudomonas aeruginosa* a- and b-type flagellins in patients with cystic fibrosis: a prospective study, 270
LAGERGÅRD TERESA, *see* FRISK *et al.*, 192
LARKIN M J, *see* PATRICK *et al.*, 99
LAU Q C, *see* POH *et al.*, 201
LEAVES N I, FALLA T J, CROOK D W M. The elucidation of novel capsular genotypes of *Haemophilus influenzae* type b with the polymerase chain reaction, 120
LEE S C, *see* CHANG *et al.*, 430
LEVETT P N, *see* BROWN *et al.*, 110
LI HUI, DILLON JO-ANNE R. Utility of ribotyping, restriction endonuclease analysis and pulsed-field gel electrophoresis to discriminate between isolates of *Neisseria gonorrhoeae* of serovar IA-2 which require arginine, hypoxanthine or uracil for growth, 208
LIVERMORE D M, *see* CHEN *et al.*, 300
LIVERMORE D M, *see* VAHABOGLU *et al.*, 294
LÜCK P C, BIRTLES R J, HELBIG J H. Correlation of MAb subgroups with genotype in closely related *Legionella pneumophila* serogroup 1 strains from a cooling tower, 50
LÜTTIKEN R, *see* REICHMANN *et al.*, 377
LUTTON DEBORAH A, *see* PATRICK *et al.*, 99
LUZZI IDA, *see* CAPRIOLI *et al.*, 348

MCBRIDE P D P, *see* SENIOR *et al.*, 176
MAGEE J T, *see* MURDOCH AND MAGEE, 148
MARSHALL A J, MILES R J, RICHARDS L. The phagocytosis of mycoplasmas, 239
MARTIN L, *see* PHAM *et al.*, 9
MARTON ANNA, *see* REICHMANN *et al.*, 377
MATSUMOTO T, *see* HIRAKATA *et al.*, 258
MATSUMOTO TETSUYA, *see* MIYAZAKI *et al.*, 169
MICHAELSEN T M, *see* IDÄNPÄÄN-HEIKKILÄ *et al.*, 335
MILES R J, *see* MARSHALL *et al.*, 237
MILLAR-JONES L, *see* RYLEY *et al.*, 436
MISAWA N, OHNISHI T, ITOH K, TAKAHASHI E. Cytotoxin detection in *Campylobacter jejuni* strains of human and animal origin with three tissue culture assay systems, 354
MIYAZAKI SHUICHI, MATSUMOTO TETSUYA, TATEDA KAZUHIRO, OHNO AKIRA, YAMAGUCHI KEIZO. Role of exotoxin A in inducing severe *Pseudomonas aeruginosa* infections in mice, 169
MOLYNEAUX PAMELA J. Human immunity to rotavirus, 397
MONTIE T C, *see* LAGACÉ *et al.*, 270
MORCK D W, *see* OWUSU-ABABIO *et al.*, 368
MORLEY K D, *see* SENIOR *et al.*, 176
MORRISSEY I, SMITH J T. Bactericidal activity of the new 4-quinolones DU-6859a and DV-7751a, 4
MOUTON R P, *see* VAN ASSELT *et al.*, 386
MPAMUGO O, DONOVAN T, BRETT M M. Enterotoxigenic *Clostridium perfringens* as a cause of sporadic cases of diarrhoea, 442
MULAZIMOGLU L, *see* VAHABOGLU *et al.*, 294
MURDOCH D A, MAGEE J T. A numerical taxonomic study of the gram-positive anaerobic cocci, 148
MUSSER J M, *see* URWIN *et al.*, 45

NASSAR F, *see* DESAI *et al.*, 224
NOBLE W C, *see* CREE *et al.*, 161
NORIMATSU MARI, ONO TOMOKO, AOKI AKEMI, OHISHI K, TAMURA Y. In-vivo induction of apoptosis in murine lymphocytes by bacterial lipopolysaccharides, 251

OBERLE K, *see* JACOBS *et al.*, 422
OHISHI K, *see* NORIMATSU *et al.*, 251
OHNISHI T, *see* MISAWA *et al.*, 354
OHNO AKIRA, *see* MIYAZAKI *et al.*, 169
OLSON M E, *see* OWUSU-ABABIO *et al.*, 368
ONO TOMOKO, *see* NORIMATSU *et al.*, 251
O'REILLY T, *see* ROONEY *et al.*, 37
ORFILA J, *see* SAYADA *et al.*, 14
OWUSU-ABABIO G, ROGERS J A, MORCK D W, OLSON M E. Efficacy of sustained release ciprofloxacin microspheres against device-associated *Pseudomonas aeruginosa* biofilm infection in a rabbit peritoneal model, 368
OXFORD J S. Quo vadis antiviral agents for herpes, influenza and HIV?, 1

PANDYA MANISHA, PILLAI PARUKUTTY, DEB MANORAMA. Rapid diagnosis of typhoid fever by detection of Barber protein and Vi antigen of *Salmonella* serotype Typhi, 185

PATIL SHRIPAD A, KATOCH KIRAN, RAMU G, SENGUPTA U. Detection of antibodies against phenolic glycolipid-1 (PGL-1), 35-kDa and 30–40-kDa components of *Mycobacterium leprae* in the cerebrospinal fluid of leprosy patients, 115
PATRICK SHEILA, STEWART LINDA D, DAMANI N, WILSON K G, LUTTON DEBORAH A, LARKIN M J, POXTON I, BROWN R. Immunological detection of *Bacteroides fragilis* in clinical samples, 99
PAULL A, *see* RYLEY *et al.*, 436
PÉLOQUIN L, *see* LAGACÉ *et al.*, 270
PHAM J N, BELL S M, HARDY M J, MARTIN L, GUIYOLE A, CARNIEL E. Susceptibility to β-lactam agents of *Yersinia enterocolitica* biotype 4, serotype O3 isolated in various parts of the world, 9
PHILLIPS I, *see* CREE *et al.*, 161
PICCOLI M, *see* SANTONI *et al.*, 360
PIGNATO SARINA, GIAMMANCO GIOVANNI, GIAMMANCO GIUSEPPE. Rambach agar and SM-ID medium sensitivity for presumptive identification of *Salmonella* subspecies I–VI, 68
PILLAI PARUKUTTY, *see* PANDYA *et al.*, 185
POH C L, LAU Q C, CHOW V T K. Differentiation of *Neisseria gonorrhoeae* IB-3 and IB-7 serovars by direct sequencing of protein IB gene and pulsed-field gel electrophoresis, 201
POPOV V L, CHEN SHENG-MIN, FENG HUI-MIN, WALKER D H. Ultrastructural variation of cultured *Ehrlichia chaffeensis*, 411
POUTREL B, *see* BOURRY *et al.*, 125
POXTON I, *see* PATRICK *et al.*, 99
POZNIAK A L, *see* DROBNIEWSKI *et al.*, 85

RAMU G, *see* PATIL *et al.*, 115
REICHMANN P, VARON EMANUELLE, GÜNTHER ELISABETH, REINERT R R, LÜTTIKEN R, MARTON ANNA, GESLIN P, WAGNER JUTTA, HAKENBECK REGINE. Penicillin-resistant *Streptococcus pneumoniae* in Germany: genetic relationship to clones from other European countries, 377
REINERT R R, *see* REICHMANN *et al.*, 377
REISSBRODT R, *see* HEUCK *et al.*, 26
RICHARDS L, *see* MARSHALL *et al.*, 237
ROCOURT J, *see* BOURRY *et al.*, 125
RODIER MARIE-HÉLÈNE, *see* EL MOUDNI *et al.*, 282
RODITI DENISE, *see* ZAPPE *et al.*, 189
ROGERS J A, *see* OWUSU-ABABIO *et al.*, 368
ROGGEN E L, *see* FRISK *et al.*, 192
ROONEY P, BILBE G, ZAK O, O'REILLY T. Dexamethasone treatment of lipopolysaccharide-induced meningitis in rabbits that mimics magnification of inflammation following antibiotic therapy, 37
RUSSELL A D, *see* BROADLEY *et al.*, 458
RUSSMANN H, *see* CAPRIOLI *et al.*, 348
RYDING U, CHRISTENSSON B, SÖDERQUIST B, WADSTRÖM T. Antibody response to *Staphylococcus aureus* collagen binding protein in patients with *S. aureus* septicaemia and collagen binding properties of corresponding strains, 328
RYLEY H C, MILLAR-JONES L, PAULL A, WEEKS J. Characterisation of *Burkholderia cepacia* cystic fibrosis patients living in Wales by PCR ribotyping, 436

SAHAY P, WEST A P, BIRKENHEAD D, HAWKEY P M. *Campylobacter jejuni* in the stomach, 75
SANTONI G, BIRARELLI P, JIN HONG L, GAMERO A, DJEU J Y, PICCOLI M. An α5β1-like integrin receptor mediates the binding of less pathogenic *Candida* species to fibronectin, 360
SAYADA C, DENAMUR E, GRANDCHAMP B, ORFILA J, ELION J. Denaturing gradient gel electrophoresis analysis for the detection of point mutations in the *Chlamydia trachomatis* major outer-membrane protein gene, 14
SCHILTZ E, *see* JACOBS *et al.*, 422
SCHNEIDER CH, *see* GRUNDMANN *et al.*, 446
SCHØNHEYDER H C, *see* KRISTENSEN AND SCHØNHEYDER, 63
SENGUPTA U, *see* PATIL *et al.*, 115
SENIOR B W, MCBRIDE P D P, MORLEY K D, KERR M A. The detection of raised levels of IgM to *Proteus mirabilis* in sera from patients with rheumatoid arthritis, 176
SERICHANTALERGS O, *see* DALSGAARD *et al.*, 216
SETHABUTR O, *see* DALSGAARD *et al.*, 216
SHARMA SAROJ, *see* GUPTA *et al.*, 33
SHIMADA T, *see* DALSGAARD *et al.*, 216
SIMON R, *see* GRUNDMANN *et al.*, 446
SIMPANYA MUKOMA F. Identification of *Candida albicans* and *C. tropicalis* with an umbelliferyl-labelled galactosaminide, 230
SLOOS J H, *see* VAN ASSELT *et al.*, 386
SMITH J T, *see* MORRISSEY AND SMITH, 4
SÖDERQUIST B, *see* RYDING *et al.*, 328
STACEY S N, *see* BIRLEY *et al.*, 81
STEVENS D A, *see* DESAI *et al.*, 224
STEWART LINDA D, *see* PATRICK *et al.*, 99
STEYN L M, *see* ZAPPE *et al.*, 189
STRACHAN S A, FRIEDLAND I R. Therapy for penicillin-resistant *Streptococcus pneumoniae*, 237
SWEET S P, COOKSON SHARON, CHALLACOMBE S J. *Candida albicans* isolates from HIV-infected and AIDS patients exhibit enhanced adherence to epithelial cells, 452

TAKAHASHI E, *see* MISAWA *et al.*, 354
TAMURA Y, *see* NORIMATSU *et al.*, 251
TATEDA K, *see* HIRAKATA *et al.*, 258
TATEDA KAZUHIRO, *see* HIRAKATA *et al.*, 141
TATEDA KAZUHIRO, *see* MIYAZAKI *et al.*, 169
TERPSTRA W J, *see* BROWN *et al.*, 110
TICHY H V, *see* GRUNDMANN *et al.*, 446
TOWNER K J, *see* CROWE *et al.*, 55

URSING J, *see* FREDERIKSEN AND URSING, 315
URWIN GILLIAN, MUSSER J M, YUAN MEI FANG. Clonal analysis of *Haemophilus influenzae* type b isolates in the United Kingdom, 45
UTTLEY A H C, *see* DROBNIEWSKI *et al.*, 85

VAHABOGLU H, HALL L M C, MULAZIMOGLU L, DODANLI S, YILDIRIM I, LIVERMORE D M. Resistance to extended-spectrum cephalosporins, caused by PER-1 β-lactamase, in *Salmonella typhimurium* from Istanbul, Turkey, 294
VAN ASSELT G J, SLOOS J H, MOUTON R P, VAN BOVEN C P A, VAN DE KLUNDERT J A M. Susceptibility of *Streptococcus pyogenes* to azithromycin, clarithromycin, erythromycin and roxithromycin *in vitro*, 386
VAN BOVEN C P A, *see* VAN ASSELT *et al.*, 386
VAN DE KEMP H, *see* BROWN *et al.*, 110
VAN DE KLUNDERT J A M, *see* VAN ASSELT *et al.*, 386
VARON EMANUELLE, *see* REICHMANN *et al.*, 377

WADSTRÖM T, *see* RYDING *et al.*, 328
WAGNER JUTTA, *see* REICHMANN *et al.*, 377
WALKER D H, *see* POPOV *et al.*, 411
WEDEGE E, *see* IDÄNPÄÄN-HEIKKILÄ *et al.*, 335
WEEKS J, *see* RYLEY *et al.*, 436
WEST A P, *see* SAHAY *et al.*, 75
WILLCOX M D P. Potential pathogenic properties of members of the "*Streptococcus milleri*" group in relation to the production of endocarditis and abscesses, 405
WILSON K G, *see* PATRICK *et al.*, 99

YAMAGUCHI K, *see* HIRAKATA *et al.*, 258
YAMAGUCHI KEIZO, *see* HIRAKATA *et al.*, 141
YAMAGUCHI KEIZO, *see* MIYAZAKI *et al.*, 169
YILDIRIM I, *see* VAHABOGLU *et al.*, 294
YUAN MEI, *see* CHEN *et al.*, 300
YUAN MEI FANG, *see* URWIN *et al.*, 45

ZAK O, *see* ROONEY *et al.*, 37
ZAPPE CATHERINE H, BARLOW DIANA, ZAPPE H, BOLTON INGRID J, RODITI DENISE, STEYN L M. 16S rRNA sequence analysis of an isolate of *Mycobacterium haemophilum* from a heart transplant patient, 189
ZAPPE H, *see* ZAPPE *et al.*, 189
ZYGMUNT M S, *see* BOWDEN *et al.*, 344